S38 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 96 | クローン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002857-29-HU (EUCTR) | 04/01/2006 | 18/08/2005 | A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease | A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease | Moderate to severe, active Crohn’s disease MedDRA version: 3.2;Level: LLT;Classification code 10011401 | Product Name: STA-5326 mesylate Product Code: S38 Other descriptive name: STA-6838, STA-5326 m, S38 | Synta Pharmaceutical Corporation | NULL | Not Recruiting | Female: yes Male: yes | 282 | Hungary |